Risk Identification of the GlucoTab System in Routine Use

A Study to Identify Risks in Routine Use of the GlucoTab System for Glycaemic Management in Non-critically Ill Patients With Type 2 Diabetes at General Wards

Identification of risks of the GlucoTab system in routine use.

A study to identify risks in routine use of the GlucoTab system for glycaemic management in non-critically ill patients with type 2 diabetes at general wards.

Inclusion Criteria:

• informed consent obtained after being advised of the nature of the study
• type 2 diabetes or new-onset hyperglycaemia which require s.c. insulin therapy during hospital stay
• diabetes therapy supported by GlucoTab system

Exclusion Criteria:

• type 1 diabetes mellitus
• intravenous insulin therapy
• hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require intravenous insulin therapy
• gestational diabetes or pregnancy
• known or suspected allergy to certain insulin types, named in the user manual
• total parenteral nutrition (TPN)
• any mental condition rendering the patient incapable of giving his consent